Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine for prevention of recurrent idiopathic angioedema attacks
2013-003002-91Phase 2Terminated
- Sponsor
- Menarini Group
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bilastine in idiopathic angioedema (2 arms), sponsored by Menarini Group. Primary endpoint: Reduction in number of days with moderate to severe angioedema. Started Aug 2013; status: terminated.
02
Drugs
bilastine
03
Conditions
idiopathic angioedema
Beyond the preview
Go deeper on 2013-003002-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003002-91.